Despite a steady decline in incidence, gastric cancer (GC) is the second most common cause of cancer-related deaths worldwide ([@bib21]; [@bib14]). Most GC patients in the East are diagnosed with early-stage disease ([@bib34]; [@bib21]; 2008), whereas GC patients in the West present with locally advanced (inoperable), metastatic or recurrent disease and are treated by cytotoxic combination chemotherapy ([@bib7]; [@bib23]; [@bib4]). Median overall survival (OS) of patients treated with palliative chemotherapy is 10--12 months ([@bib7]). Targeted therapy has been investigated in this patient group, and the combination of trastuzumab with chemotherapy demonstrated a modest OS benefit in patients with *HER2*-positive advanced GC ([@bib5]). However, no survival benefit was seen when bevacizumab, an antibody against VEGF ([@bib42]), everolimus, a drug targeting mTOR ([@bib43]), or the EGFR antibodies panitumumab or cetuximab ([@bib28]; [@bib45]) were trialed in non-selected GC patients. Because of the poor prognosis of GC patients, there is a need to identify new potential targets and develop diagnostic tests to identify patients most likely to benefit from targeted therapies.

Fibroblast growth factor receptors (FGFR1--4) are transmembrane tyrosine kinase receptors ([@bib11]; [@bib39]; [@bib6]; [@bib45]). FGF binding to the monomeric receptor triggers dimerisation and transphosphorylation of tyrosine residues in the kinase domain ([@bib11]; [@bib26]; [@bib39]; [@bib6]). This pathway regulates a variety of cellular functions including cell proliferation, migration and differentiation, which are fundamental to embryonic development, angiogenesis and wound healing ([@bib11]; [@bib12]; [@bib39]; [@bib6]).

Dysregulation of the FGFR signalling pathway due to receptor overexpression, gene amplification, mutation or aberrant transcriptional regulation is associated with cancer development and progression in multiple myeloma and cancers of the breast, bladder, lung, endometrium and prostate ([@bib20]; [@bib8]; [@bib15]; [@bib37]; [@bib25]; [@bib39]; [@bib6]).

In preclinical models of GC, *FGFR2* amplification was associated with increased tumour cell proliferation and survival, and conferred sensitivity to drugs targeting this pathway, such as the FGFR selective small molecule inhibitors AZD4547 and BGJ398, and anti-FGFR2 antibodies ([@bib3]; [@bib50]; [@bib13]; [@bib16]; [@bib49]; [@bib48]). Studies have reported *FGFR2* amplification in up to 10% of Asian GC patients ([@bib9]; [@bib22]; [@bib29]), and *FGFR2* amplification was recently described in Western GC cohorts ([@bib9]; [@bib10]; [@bib31]). Each of these studies employed a different platform to assess gene amplification, including RT-PCR, fluorescence *in situ* hybridisation (FISH) and SNP arrays.

This study used FISH to compare the frequency of *FGFR2* amplification in large series of GCs from UK, Chinese and Korean patients, the overlap of *FGFR2* and *HER2* amplification, and the association of *FGFR2* amplification with clinicopathological variables and OS.

Material and methods
====================

Patient cohorts
---------------

The UK, Chinese and Korean GC cohorts consisted of 408, 197 and 356 patients, respectively, with sporadic gastric adenocarcinoma who underwent surgical resection at Leeds General Infirmary, the United Kingdom (1970----2004), Shanghai Renji Hospital, China (2007--2010) and Seoul National University Hospital, South Korea (1996), respectively ([Table 1](#tbl1){ref-type="table"}). Clinical outcome was determined from date of surgery until last seen or mortality status obtained in 2009, 2011 and 2003, for the UK, Chinese and Korean cohorts, respectively. At the end of the study period, 73% and 33% of UK and Chinese patients had died. Median (range) follow-up time was 1.7 years (0--20.5 years), 2.4 years (1 month--4.6 years) and 5.5 years (2 months--8 years) for UK, Chinese and Korean cohorts, respectively.

Tissue microarray construction
------------------------------

Haematoxylin/eosin-stained sections of resected specimens were reviewed, and blocks with the highest tumour cell density selected for tissue microarray (TMA) construction. TMAs were constructed by random sampling of 3--6, 0.6 mm cores from each tumour and three cores from matched normal mucosa (UK cohort), one 1-mm core from each tumour (Korean cohort), two to four 0.6-mm cores from each tumour and two from matched normal mucosa (Chinese cohort). Four (Korean/Chinese) or 5 *μ*m (UK) sections were cut from each TMA for gene copy-number analysis. Full sections were cut from 26 UK *FGFR2*-amplified GC specimens to assess amplification heterogeneity within individual tumours. TMA and full sections were quality controlled by an experienced histopathologist.

*FGFR2* FISH
------------

The *FGFR2* FISH probe was generated in house by AstraZeneca by directly labelling BAC RP11-62L18 (Invitrogen, Grand Island, New York, USA) DNA with Spectrum Red (ENZO, Exeter, UK, 02N34-050) using a nick translation-based method (Abbott Park, IL, USA, 07J00-001) according to the manufacturer\'s instructions. Pericentromeric Spectrum Green labelled chromosome 10 probe (CEP10, Vysis, 32-132010) was used as an internal control. FISH was performed as described previously ([@bib48]). Sections were deparaffinized and pretreated using the SpotLight Tissue Kit (Invitrogen, 00--8401) according to the manufacturer\'s instructions. Sections and *FGFR2/*CEP10 probes were co-denaturated at 80 °C for 5 min and hybridised at 37 °C for 48 h. Excess probe was removed with post-hybridisation wash buffer (0.3% NP40/1 × SSC) at 75.5 °C for 5 min, then 2 × SSC at room temperature for 2 min. Sections were counterstained with 0.3 μg ml^−1^ DAPI (Vector, H-1200) and coverslipped. *FGFR2* and CEP10 signals were scored under a fluorescence microscope (Olympus, Center Valley, PA, USA, BX61). Scoring was adopted from ([@bib44]). Fifty nuclei were evaluated/case. *FGFR2* gene copy-number and *FGFR2*/CEP10 ratio was classified as follows: *FGFR2* amplification (score 6): *FGFR2*/CEP10 ratio ⩾2 or *FGFR2* gene clusters in ⩾10% tumour cells; high polysomy (score 5): *FGFR2*/CEP10 ratio \<2 and ⩾4 copies of *FGFR2* in ⩾40% tumour cells; low polysomy (score 4): *FGFR2*/CEP10 ratio \<2 and ⩾4 copies of *FGFR2* in 10--39% tumour cells; high trisomy (score 3): *FGFR2*/CEP10 ratio \<2 and 3 copies of *FGFR2* in ≥40% tumour cells and \<10% tumour cells having ⩾4 copies of *FGFR2*; low trisomy (score 2): *FGFR2*/CEP10 ratio \<2 and 3 copies of *FGFR2* in 10--39% tumour cells and \<10% tumour cells having ⩾4 copies of *FGFR2*; disomy (score 1): two copies of *FGFR2* in 90% of tumour cells. Scoring was performed independently by two observers at AstraZeneca.

Assessment of FGFR2 amplification heterogeneity
-----------------------------------------------

Intratumoral *FGFR2* amplification heterogeneity was assessed in TMA and full sections from 26 UK cases with *FGFR2* amplification, and was defined as the presence of areas with different FISH scores within the same tumour in full sections and presence of different FISH scores in cores from the same tumour in TMA sections. Scoring was performed independently by two observers.

*HER2* FISH
-----------

*HER2*/CEP17 probe (Vysis, 30-161060) was used according to the manufacturer\'s instructions. Fifty tumour nuclei were scored/case. Tumours with an average *HER2* gene copy number \>6 or a *HER2*/CEP17 ratio ⩾2 were defined as *HER2* amplified. Scoring was performed independently by two observers.

Combined FGFR2 and HER2 FISH
----------------------------

To detect *FGFR2* and *HER2* copy number simultaneously, a four-colour FISH probe was generated. The above *FGFR2*/CEP10 probes were combined with a *HER2* probe generated by labelling BAC RP11-94L15 DNA (Invitrogen) with Spectrum Gold (ENZO, ENZ-42843) and a CEP17 Spectrum Aqua probe (Vysis, 32-111017) as internal control using experimental conditions described for *FGFR2* FISH. This analysis was performed only in cases identified as *FGFR2* and *HER2* amplified in the TMA. Scoring was performed independently by two observers.

Statistical analysis
--------------------

Data from each cohort were analysed individually. The following variables were used for statistical analysis: tumour histology type (Laurén classification, ([@bib27])) tumour grade of differentiation (WHO classification, ([@bib17])) depth of invasion (pT), lymph node status (pN), distant metastasis status (pM), resection margin status (R) and stage (TNM classification sixth edition) ([@bib36]).

Chi-square tests were used to compare clinicopathological characteristics between cohorts. For association of *FGFR2* amplification with clinicopathological characteristics, logistic regression models were fitted in both univariate and multivariate analysis, and *P*-values were computed by log-likelihood Chi-square test. In multivariate models, age, gender and factors that showed significant association in univariate analysis (pN and grade of differentiation) were included.

For OS, patients were categorised by *FGFR2* status into amplified (FISH score 6) and non-amplified (FISH score 1--5). Data were analysed using Kaplan--Meier ([@bib24]) and log-rank statistics. Univariate and multivariate Cox proportional hazard models were fitted to evaluate *FGFR2* status including variables for age, gender, grade of differentiation and stage ([@bib36]). Statistical tests were two-sided, *P*\<0.05 was considered significant. Analyses were carried out using R (version 2.10.1).

All studies were performed with the approval of Local Research Ethics committees and were conducted in accordance with the Declaration of Helsinki.

Results
=======

Comparison of patient characteristics and clinicopathological variables between GC cohorts are detailed in [Table 1](#tbl1){ref-type="table"}. UK patients were significantly older at the time of diagnosis compared with Asian cohorts (UK/Chinese *P*\<0.0001, UK/Korean *P*=0.0003). The frequency of intestinal type GC was significantly higher in the UK cohort compared with Asian cohorts (UK/Chinese *P*\<0.0001, UK/Korean *P*\<0.0001). The frequency of well, moderately and poorly differentiated GC was different between all cohorts (UK/Chinese *P*\<0.0001, UK/Korean *P*\<0.0001, Chinese/Korean *P*\<0.0001). There was a significant difference in disease stage distribution between cohorts, with stage III disease more common in Chinese patients (UK/Chinese *P*\<0.0001, Chinese/Korean *P*\<0.0001). All UK patients were treated by surgery alone, while 66% of Chinese and 53% of Korean patients received adjuvant chemotherapy. No patients received neoadjuvant chemotherapy or radiotherapy.

FGFR2 copy number
-----------------

Results were obtained from a total of 961 cases ([Table 2](#tbl2){ref-type="table"}). *FGFR2* amplification frequency was 7.4%, 4.6% and 4.2% in the UK, Chinese and Korean cohorts, respectively, and did not differ significantly (UK/Chinese *P*=0.258, UK/Korean *P*=0.092, Chinese/Korean *P*=0.983, UK/Chinese/Korean *P*=0.586). *FGFR2* polysomy was observed in 35.1%, 44.2% and 21.3% of UK, Chinese and Korean cohorts, respectively, and was significantly lower in the Korean cohort (UK/Korean *P*\<0.0001, Korean/Chinese *P*\<0.0001, UK/Chinese/Korean *P*\<0.0001). Correspondingly, there was a significantly higher frequency of *FGFR2* disomy in the Korean cohort (UK/Korean *P*\<0.0001, Korean/Chinese *P*\<0.001, UK/Chinese/Korean *P*\<0.001).

Association of *FGFR2* copy number with clinicopathological parameters
----------------------------------------------------------------------

The relationship between *FGFR2* amplification and clinicopathological parameters was analogous between the cohorts; hence, a combined analysis of all three cohorts is presented. Univariate and multivariate analyses of all 961 patients showed that *FGFR2* amplification was significantly more common in patients with higher pN category (*P*\<0.0001). For the analysis of grade of tumour differentiation, the small number of patients with grade 4 tumours (*n*=24) were grouped together with grade 3 tumours. Statistical analysis showed that the prevalence of *FGFR2* amplification was significantly lower in grade 2 (moderately differentiated) tumours compared with grade 1 (well differentiated) or grade 3 and 4 (poorly differentiated/undifferentiated) tumours (*P*\<0.01). There was no association of *FGFR2* amplification with age, gender, histological subtype ([Table 3](#tbl3){ref-type="table"}) or tumour location (*P*=0.716, data not shown).

Association of FGFR2 copy number with overall survival
------------------------------------------------------

Type of treatment and other patient characteristics differed significantly between the three cohorts. Therefore, the relationship between *FGFR2* FISH status and overall survival was analysed separately. Median OS was significantly shorter in patients with *FGFR2* amplified GC compared with patients with *FGFR2* non-amplified GC in UK (*P*\<0.0001) and Korean (*P*=0.0073) cohorts by univariate analysis ([Table 4](#tbl4){ref-type="table"}). A similar trend was observed for the Chinese cohort but did not achieve significance (*P*=0.0646; [Figure 1](#fig1){ref-type="fig"}). Multivariate survival analysis from the Cox proportional hazard model adjusting for age, gender and grade of tumour differentiation confirmed *FGFR2* amplification status as an independent prognostic marker in the UK cohort (*P* =0.0002; [Table 4](#tbl4){ref-type="table"}).

To assess whether there was an effect of adjuvant chemotherapy treatment on the prognostic value of *FGFR2* amplification, a subset analysis was performed in patients treated by surgery only *vs* patients treated by adjuvant chemotherapy after surgery. Results from Korean and Chinese cohorts were pooled for this analysis. *FGFR2* amplification was similarly predictive for shorter OS in patients treated with adjuvant chemotherapy (*P*=0.002) and the surgery only group (*P*=0.03).

UK and Korean patients with *FGFR2* polysomy GC (score 4--5) had a significantly shorter OS when compared with others with *FGFR2* non-amplified disease (score 1--3) in univariate analysis (UK cohort *P*=0.0427; Korean cohort *P*=0.0434) that was not significant in multivariate analysis adjusting for age, gender, grade of differentiation and stage ([Table 4](#tbl4){ref-type="table"}). No relationship was seen in the Chinese cohort.

*FGFR2* amplification heterogeneity
-----------------------------------

Seven of 29 UK *FGFR2* amplified GCs (24.1%) displayed intratumoral heterogeneity within TMAs. Tissue sections were unavailable for 3/29 GCs. Analysis of full sections confirmed *FGFR2* amplification in 23/26 cases and intratumoral heterogeneity in six cases, which also showed heterogeneity in the TMA study. Three cases found to be *FGFR2* amplified in the TMA study showed no evidence of *FGFR2* amplification in full sections, most likely related to *FGFR2* amplification heterogeneity.

*FGFR2* and *HER2* amplification are predominantly exclusive
------------------------------------------------------------

*HER2* FISH results were available from 204 and 338 of Chinese and Korean GCs; amplification was present in 14.7% and 8% of GCs, respectively. Co-amplification of *HER2* and *FGFR2* was present in one Chinese GC but not detected in any GCs from the Korean cohort. In the UK cohort, the frequency of *HER2* and *FGFR2* co-amplification was investigated in 26 full sections of GCs found to be *FGFR2* amplified in the TMA study. Two of the 26 UK GC cases showed *FGFR2* and *HER2* co-amplification. In order to assess whether co-amplification was present in the same cell, *FGFR2/HER2* four-colour FISH was performed. High-level amplifications of *HER2* and *FGFR2* (*FGFR2* average copy number \>100 and *HER2/CEP17* ratio \>10) were found in both UK GCs, and *HER2* amplification was seen in tumour cells that were *FGFR2* non-amplified and vice versa ([Figure 2D](#fig2){ref-type="fig"}). In contrast, *HER2* and *FGFR2* amplifications occurred in the same tumour cell in the single Chinese GC, but amplifications were of low level and only just satisfied the minimal amplification criteria (*FGFR2* average copy number 5.52 and *HER2*/CEP17 ratio 2.26) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

Discussion
==========

*FGFR* amplification has been reported in various cancers, including *FGFR1* amplification in ER+breast cancer and squamous cell lung cancer, and *FGFR2* amplification in triple negative breast cancer and GCs ([@bib2]; [@bib40], [@bib41]; [@bib47]; [@bib9]; [@bib10]; [@bib22]; [@bib29]; [@bib31]). Hence, there is significant interest in FGFR2 as a therapeutic target for *FGFR2*-amplified GCs, and clinical trials of FGFR inhibitors are ongoing.

There is variability in the reported incidence of FGFR2 overexpression in GC; FGFR2 protein overexpression was reported to be 30%--40% by immunohistochemistry, ([@bib19]) while the incidence of *FGFR2* amplification varies from 3 to 10% ([@bib30]; [@bib18]; [@bib9]; [@bib10]; [@bib22]; [@bib29]). Gene copy-number evaluation in solid tumour cells by FISH is widely accepted as a 'gold-standard approach\' for clinical application, and the current study is the largest to date assessing *FGFR2* amplification by FISH in patients with resectable GC from three different countries, Korea, China and UK. The prevalence of *FGFR2* amplification was investigated in a total of 961 GCs and was 7.4%, 4.6% and 4.2% in UK, Chinese and Korean GCs, respectively, with no significant difference of incidence between cohorts. Our results are similar to those reported previously for Korean ([@bib22]) and Japanese cohorts ([@bib29]). In addition to *FGFR2* amplification, we found a significant incidence of *FGFR2* polysomy in GC, which was significantly higher in UK (35.1%) and Chinese (44.2%) GC cohorts than in the Korean cohort (21.3%). Further work is required to demonstrate whether *FGFR2* polysomy is related to tumour growth, survival and sensitivity to therapeutic intervention.

The observation that *FGFR2* amplification was significantly associated with lymph node disease suggests that this molecular aberration may contribute to the development of metastasis. An association between *FGFR2* amplification and lymphatic invasion was recently reported ([@bib22]).

It has been reported that *FGFR2* amplification is more frequently found in diffuse type GC compared with intestinal type GC ([@bib32]). In contrast, our study did not find an association of *FGFR2* amplification with histological subtype according to the Laurén classification, which is in agreement with findings recently reported for another Korean GC cohort ([@bib22]). This contrasts with *HER2* gene amplification, which is associated with the intestinal subtype of gastric cancer ([@bib4]).

The current study suggests that *FGFR2* amplification is a molecular factor related to poor prognosis in patients with resectable GC, irrespective of ethnic origin and irrespective of the underlying significant differences in clinicopathological parameters, survival and treatment between cohorts from Asia and the United Kingdom. The potential usefulness of *FGFR2* amplification as a predictive factor for response to *FGFR2* targeting therapies remains to be evaluated in patients with GC.

Amplification of *HER2* has been identified in 6--35% of patients with GC ([@bib4]); however, the majority of recent studies have reported incidences of 6--13% ([@bib35]; [@bib38]; [@bib1]; [@bib33]; [@bib46]). *HER2* amplification has led to the successful development and approval of trastuzumab in patients with GC ([@bib5]). In the present study, we assessed the overlap between *FGFR2* and *HER2* amplification. Only 3/50 *FGFR2*-amplified samples (3/961 of total population samples) were also *HER2* amplified, confirming that *HER2* and *FGFR2* amplifications are usually mutually exclusive ([@bib9]). Interestingly, low-level *HER2* and *FGFR2* amplifications were detected in the same tumour cells in one Chinese GC, whereas in two UK GCs tumour cells with high-level *HER2* amplification were located in a different area to tumour cells with high-level *FGFR2* amplification. The findings in these latter two GCs suggest that *FGFR2-* and *HER2-* amplified tumour cells may have developed from different tumour cell clones with differing genetic characteristics. In these patients, combined *FGFR2* and *HER2* inhibitor therapies might be required for durable and potent antitumour responses.

We found evidence for intratumoral heterogeneity of *FGFR2* amplification in about 25% of GCs, indicating that there is a potential for missing areas of amplification especially when analysis is performed on small biopsies, rather than sections from resection specimens. Similar intratumoral heterogeneity has been reported for *HER2* amplification in GC, leading to a recommendation that multiple biopsies should be assessed to determine *HER2* status of a tumour.

In conclusion, this is the largest study of *FGFR2* FISH in GC and the first study to compare the incidence of *FGFR2* amplification in UK and Asian cohorts, demonstrating a similar incidence across cohorts. Furthermore, our data show that *FGFR2* amplification is associated with lymph node metastasis and related to poor OS. Overall, this study suggests that *FGFR2* may represent an attractive therapeutic target in a subgroup of GCs, irrespective of ethnicity, and FISH methodology could be used for patient selection.
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![**Kaplan--Meier OS analysis using *FGFR2* FISH score in three separate patient cohorts.** Median OS and 95% CI for pairwise comparisons are provided.](bjc2013802f1){#fig1}

![**Dual-colour FISH shows *FGFR2* copy-number normal (A), copy-number increase (B) and amplification (C).** Red and green signals highlight *FGFR2* gene and centromere 10 probes, respectively. Four-colour FISH reveals distinct tumour regions with either *FGFR2* or *HER2* amplification (**D**). Gold and aqua probes highlight *HER2* and centromere 17.](bjc2013802f2){#fig2}

###### Comparison of the clinicopathological characteristics between UK, Chinese and Korean gastric cancer cohorts

                                  **UK cohort (*****n*****=408)**   **Chinese cohort (*****n*****=197)**   **Korean cohort (*****n*****=356)**                  
  ------------------------------ --------------------------------- -------------------------------------- ------------------------------------- ------ -------- ------
  **Age (years)**                                                                                                                                               
  Median                                        70                                                                         62                             59     
  Range                                       13--96                                                                     18--87                         28--82   
  **Gender**                                                                                                                                                    
  Male                                          255                                 62.5                                   133                   67.5    247    69.4
  Female                                        153                                 37.5                                   64                    32.5    109    30.6
  **Grade of differentiation**                                                                                                                                  
  G1                                            45                                  11.0                                    3                    1.5      20    5.6
  G2                                            103                                 25.2                                   40                    20.3    173    48.6
  G3                                            250                                 61.3                                   133                   67.5    161    45.2
  G4                                             1                                  0.2                                    21                    10.7     2     0.6
  Unknown                                        9                                  2.2                                     0                    0.0      0     0.0
  **Laurén subtype**                                                                                                                                            
  Intestinal                                    244                                 59.8                                   66                    33.5    170    47.8
  Diffuse                                       96                                  23.5                                   87                    44.2    172    48.3
  Mixed                                         64                                  15.7                                   44                    22.3     14    3.9
  Unknown                                        4                                  1.0                                     0                    0.0      0     0.0
  **Stage**                                                                                                                                                     
  I                                             115                                 28.2                                   15                    7.6     121    34.0
  II                                            81                                  19.9                                   45                    22.8     83    23.3
  III                                           151                                 37.0                                   100                   50.8     89    25.0
  IV                                            60                                  14.7                                   37                    18.8     63    17.7
  unknown                                        1                                  0.2                                     0                    0.0      0     0.0
  **Depth of invasion (pT)**                                                                                                                                    
  T1                                            56                                  13.7                                    7                    3.6      67    18.8
  T2                                            140                                 34.3                                   20                    10.2    167    46.9
  T3                                            201                                 49.3                                   157                   79.7    114    32.0
  T4                                            11                                  2.7                                    13                    6.6      8     2.2
  **Lymph node status (pN)**                                                                                                                                    
  N0                                            136                                 33.3                                   51                    25.9    121    34.0
  N1                                            163                                 40.0                                   88                    44.7    127    35.7
  N2                                            68                                  16.7                                   34                    17.3     58    16.3
  N3                                            40                                  9.8                                    24                    12.2     50    14.0
  **Distant metastasis (pM)**                                                                                                                                   
  M0                                            391                                 95.8                                   182                   92.4    334    93.8
  M1                                            17                                  4.2                                    15                    7.6      22    6.2
  **Adjuvant chemotherapy**                                                                                                                                     
  No                                            408                                100.0                                   36                    18.3    146    41.0
  Yes                                            0                                  0.0                                    129                   65.5    188    52.8
  Unknown                                        0                                  0.0                                    32                    16.2     22    6.2

###### *FGFR2* FISH analysis

                       **UK cohort (*n*=408)**   **Chinese cohort (*****n*****=197)**   **Korean cohort (*****n*****=356)**                
  -------------------- ------------------------- -------------------------------------- ------------------------------------- ------ ----- ------
  Disomy               142                       34.8                                   39                                    19.8   190   53.4
  Low trisomy          65                        15.9                                   51                                    25.9   63    17.7
  High trisomy         28                        6.9                                    11                                    5.6    12    3.4
  Low polysomy         87                        21.3                                   51                                    25.9   66    18.5
  High polysomy        56                        13.7                                   36                                    18.3   10    2.8
  Gene amplification   30                        7.4                                    9                                     4.6    15    4.2

                    ***P*****-values**[a](#t2-fn2){ref-type="fn"} **(univariate)**   ***P*****-values**[b](#t2-fn3){ref-type="fn"} **(multivariate)**                  
  ---------------- ---------------------------------------------------------------- ------------------------------------------------------------------ --------------- ---------------
  1--5 *vs* 6                                   0.2584                                                            0.0921                                   0.9827          0.5855
  1--3 *vs* 4--5                                0.0664                                                        8.96 × 10^−8^                             1.90 × 10^−8^   3.73 × 10^−9^

Abbreviations: FGFR2=fibroblast growth factor receptor 2; FISH=fluorescent *in situ* hybridisation.

*P*-values contrasted for a given pair of cohorts are computed from *χ*^2^-test by collapsing score 1--5 subjects in 1--5 *vs* 6 comparison and score 1--3 and score 4--5 subjects, respectively, in 1--3 *vs* 4--5 comparison.

Multivariate *P*-values are from a log-likelihood ratio test after adjusting for age, gender, stage, grade and Lauren subtype.

###### Comparisons of clinicopathological characteristics by *FGFR2* amplification status

                         ***FGFR2*** **non-amplified (FISH 1--5)**   ***FGFR2*** **amplified (FISH 6)**                                              
  --------------------- ------------------------------------------- ------------------------------------ --------- ------- ------------------------- ------------------------------------------------------
  **Characteristics**                     ***n***                                  **%**                  ***n***   **%**  ***P*****-value (uni)**   ***P*****-value (multi)**[a](#t3-fn1){ref-type="fn"}
  **Age**                                                                                                                                            
  \<median age                              444                                      95                     25        5                               
  ⩾median age                               462                                      94                     29        6    0.1873                     
  **Gender**                                                                                                                                         
  Male                                      602                                      95                     33        5                               
  Female                                    305                                      94                     21        6    0.7480                     
  **Grade**                                                                                                                                          
  1                                         64                                       94                      4        6                               
  2                                         309                                      98                      7        2                               
  3                                         501                                      92                     43        8                               
  4                                         24                                      100                      0        0    0.0176                    0.0073
  **Laurén subtype**                                                                                                                                 
  Intestinal                                459                                      96                     21        4                               
  Diffuse                                   329                                      93                     26        7                               
  Mixed                                     115                                      94                      7        6    0.1793                    0.2248
  **Stage**                                                                                                                                          
  1, 2                                      442                                      96                     18        4                               
  3, 4                                      464                                      93                     36        7    0.1021                    0.1442
  **T**                                                                                                                                              
  1                                         126                                      97                      4        3                               
  2                                         306                                      94                     21        6                               
  3                                         444                                      94                     28        6                               
  4                                         31                                       97                      1        3    0.5671                    0.4805
  **N**                                                                                                                                              
  0                                         304                                      99                      4        1                               
  1                                         356                                      94                     22        6                               
  2                                         146                                      91                     14        9                               
  3                                         100                                      88                     14       12    1.22 × 10^−5^             \<0.0001
  **M**                                                                                                                                              
  0                                         856                                      94                     51        6                               
  1                                         51                                       94                      3        6    0.4456                    0.4281

*P*-value is calculated from logistic regression adjusting for age and gender.

###### Analysis of prognostic value of *FGFR2* amplification (FISH 6) or polysomy (FISH 4--5) status for overall survival (Cox proportional hazard model)
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